BIAL has reported the completion of the full dose regimen for the first subject in the multicentre Phase II ACTIVATE trial of the allosteric activator of beta-glucocerebrosidase (GCase), BIA 28 ...

It acquired rights to taligurase alfa, a form of the enzyme glucocerebrosidase in development for the treatment of Gaucher's disease, from Protalix Biotherapeutics in Carmiel, Israel. Protalix has ...